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To the editor: 
 
Increased expression of PLS3 correlates with better outcome in Sézary syndrome 
 
Patients with Sézary syndrome (SS), a rare erythrodermic and leukemic form of cutaneous T cell 
lymphoma, have a poor prognosis with a 5-year overall survival (OS) of 20-42% and a median 
OS between 2.5 and 5 years (Bernengo et al., 1998;Diamandidou et al., 1999;Kim et al., 
2003;Agar et al., 2010;Talpur et al., 2012;Kubica et al., 2012).  
Prognostic factors associated with a worse survival reported in SS include advanced age 
(Diamandidou et al., 1999;Kim et al., 2003;Foulc et al., 2003;Agar et al., 2010;Talpur et al., 
2012;Kubica et al., 2012), short duration of skin lesions before diagnosis of SS (Foulc et al., 
2003), previous history of mycosis fungoides (MF) (Bernengo et al., 1998;Kubica et al., 2012), 
elevated serum lactate dehydrogenase levels (Bernengo et al., 1998;Diamandidou et al., 
1999;Foulc et al., 2003;Agar et al., 2010;Talpur et al., 2012;Kubica et al., 2012), (the degree of) 
nodal involvement (Diamandidou et al., 1999;Kim et al., 2003), and factors reflecting blood 
tumor burden, such as increased leukocyte counts (Bernengo et al., 1998;Vidulich et al., 
2009;Talpur et al., 2012) or high Sézary cell counts (Bernengo et al., 1998). 
However, the results of these studies are not consistent, which may be due to different diagnostic 
criteria of SS, such as inclusion of patients without a T-cell clone in the peripheral blood, and 
analysis of mixed populations of patients with SS and erythrodermic MF.  
Recently we investigated the diagnostic significance of a large number of immunophenotypic 
and molecular biomarkers for SS in a group of Sézary patients (Boonk et al., 2016) that fulfilled 
the diagnostic criteria of the World Health Organization - European Organization for Research 
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and Treatment of Cancer (WHO-EORTC) classification (Willemze et al., 2005). None of these 
patients had a history of MF. Molecular biomarkers diagnostic for SS were copy number 
alterations in MYC (gain) and/ or MNT (loss), increased expression of DNM3, TWIST1, EPHA4 
and PLS3 and decreased expression of STAT4.  
Here we investigated the prognostic significance of these molecular biomarkers and previously 
reported clinical prognostic markers using the same cohort of Sézary patients. Between 
September 2009 and October 2013 sixty-four SS patients from six EORTC centers, including 
Helsinki (Finland), London (England), Leiden (Netherlands), Mannheim (Germany), Turin 
(Italy) and Paris (France) were included and followed until 30 January 2015. At inclusion of the 
study, clinical variables (gender, age at diagnosis, duration of skin lesions before diagnosis SS, 
lymph node involvement, leukocyte count, absolute CD4 count and Sézary cell count) were 
recorded and peripheral blood samples were collected for copy number variation and gene 
expression qPCR analysis, as described previously (Boonk et al., 2016). Lymph node 
involvement was defined by presence of enlarged lymph nodes of 1.5 cm or larger in the longest 
transverse diameter on computed tomography scan or histologically confirmed lymph node 
involvement.  
Aberrant gene expression in the SS samples was compared to samples from patients with 
erythrodermic inflammatory dermatoses (EID)  and healthy controls. ROC curve analysis was 
used to determine fixed cut-off thresholds for each individual gene expression qPCR assay with a 
specificity of 100% and an accuracy above 0.80. An one-tailed Mann-Whitney test was applied 
to test for significant differential expression between the SS and EID samples. P-values below 
0.05 were regarded as statistically significant. The results of aberrant expression of genes DNM3, 
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TWIST1, EPHA4, PLS3 and STAT4 were included in the statistical analysis. A more detailed 
method section including these thresholds is added in the supplementary material. 
Survival was calculated with the Kaplan-Meier method from the date of diagnosis until the 
patient’s death or date of last follow-up. The median follow-up time after diagnosis was 45 
months (range, 1-129 months). Twenty seven patients died during follow-up, including 21 SS 
related deaths. The disease-specific survival (DSS) after 1, 2, 3 and 5 years was 89%, 82%, 76% 
and 59%, respectively, and OS was 86%, 79%, 72% and 49%, respectively.   
Univariate analysis of parameters with possible prognostic significance for DSS and OS was 
performed using Cox proportional hazards regression analysis and parameters that were 
significant at the 0.1 level were included in a multivariate analysis model. P-values below 0.05 
were regarded as statistically significant.   
Both in univariate and multivariate analysis upregulation of PLS3 was associated with a 
significantly better outcome for DSS and OS (multivariate P = 0.006 and P = 0.002, 
respectively). Patients with upregulation of PLS3 had a median survival of 71 months (range, 9-
129) compared to only 33 months (range, 1-72) in SS patients with normal expression of PLS3 
(Figure 1). Upregulation of DNM3 and TWIST1 were associated with a better OS in univariate 
analysis (P = 0.008 and P = 0.043, respectively), but not in multivariate analysis (P = 0.658 and 
P = 0.342, respectively). Gain of MYC, loss of MNT, upregulation of EPHA4 and 
downregulation of STAT4 showed no association with DSS and OS (Table 1).   
Of the clinical parameters both univariate and multivariate analysis showed that leukocyte count 
was a significant prognostic factor for DSS and OS (multivariate P = 0.005 and P = 0.005, 
respectively), while gender, age, duration of skin lesions before diagnosis, lymph node 
involvement, absolute CD4 count and Sézary cell count were not (Table 1).   
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PLS3 (T-plastin) is an actin-binding protein that is expressed in all normal cells of solid tissues 
that have a replicative role, but is normally not expressed in T cells (Lin et al., 1999). Expression 
of PLS3 has been described as a specific marker of Sézary cells (Nebozhyn et al., 2006;Jones et 
al., 2012). Studies investigating the mechanism underlying dysregulation of PLS3 expression in 
SS cells found no evidence for PLS3 mutations within coding or promoter regions, but 
demonstrated significant hypomethylation of CpG dinucleotides 95-99 within the PLS3 CpG 
island which was restricted to the PLS3+ cells (Jones et al., 2012). Reanalysis of recently 
published DNA methylation profiles (van Doorn et al., 2016) from 9 Sézary patients and 4 
healthy controls included in this study confirmed this correlation between DNA methylation and 
PLS3 expression (data not shown). A recent study found that constitutive PLS3 expression was 
associated with apoptotic resistance to etoposide and suggested a role for cell survival in SS 
(Begue et al., 2012). How T-plastin expression is linked to a better outcome in Sézary patients is 
not known and should be the subject of further study.  
Although for a rare disease as SS the number of included patients is relatively high, a limitation 
of this study is a small sample size yielding wide confidence intervals and these observations 
should be confirmed in an independent study. 
In conclusion, we show that upregulation of PLS3 is associated with a favorable disease outcome 
in patients with SS and that increased leukocyte count is a significant adverse prognostic factor 
for survival.  
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Table:  
 
 
Table 1. Results of univariate and multivariate analysis for variables at Sézary syndrome 
diagnosis. Parameters significant at the 0.1 level were included in multivariate analysis.  
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Variables 
Median 
survival 
Univariate analysis 
DSS 
Multivariate 
analysis DSS 
Univariate analysis 
OS 
Multivariate 
analysis OS 
  (months) 
HR (95% 
CI) 
P-
value 
HR (95% 
CI) 
P-
value 
HR (95% 
CI) 
P-
value 
HR (95% 
CI) 
P-
value 
Gain in copy number 
of MYC      0.843       0.366     
Yes n=21 72 (1-129) 
0.90 (0.32-
2.54)       
0.66 (0.26-
1.63)       
No n=31 49 (7-86) 1       1       
Loss in copy number 
of MNT     0.355       0.388     
Yes n=35 68 (1-129) 
0.61 (0.22-
1.74)       
0.68 (0.28-
1.65)       
No n=17 49 (7-80) 1       1       
Upregulation of 
DNM3     0.337       0.008   0.658 
Yes n=36 71 (9-129) 
0.56 (0.17-
1.83)       
0.29 (0.12-
0.72)   
0.74 (0.20-
2.75)   
No n=13 33 (1-72) 1       1   1   
Upregulation of 
TWIST1     0.197       0.043   0.342 
Yes n=32 71 (1-129) 
0.48 (0.16-
1.46)       
0.39 (0.16-
0.97)   
0.57 (0.18-
1.81)   
No n=17 31 (7-80) 1       1   1   
Upregulation of 
EPHA4     0.312       0.311     
Yes n=32 49 (7-129) 
1.95 (0.53-
7.12)       
1.70 (0.61-
4.74)       
No n=17 68 (1-80) 1       1       
Upregulation of PLS3     0.027   0.006   0.001   0.002 
Yes n=32 71 (9-129) 
0.29 (0.10-
0.87)   
0.14 (0.03-
0.56)   
0.19 (0.07-
0.49)   
0.12 (0.03-
0.46)   
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No n=17 33 (1-72)  1   1   1   1   
Downregulation of 
STAT4     0.356       0.250     
Yes n=44 68 (1-129) #       
3.28 (0.43-
24.77)       
No n=5 Not reached  1       1       
Gender     0.665       0.830     
Female n=25 49 (1-129) 
1.21 (0.51-
2.85)       
0.92 (0.43-
1.98)       
Male n=39 68 (1-115) 1       1       
Age at SS diagnosis 
(y) n=64   
1.01 (0.96-
1.05) 0.827     
1.00 (0.97-
1.04) 0.850     
Duration skin lesions 
n=60    
0.98 (0.96-
1.00) 0.075 
0.99 (0.97-
1.02) 0.447 
0.99 (0.97-
1.00) 0.152     
Lymph node 
involvement     0.356       0.420     
Yes n=18 49 (1-74) 
1.82 (0.51-
6.53)       
1.55 (0.53-
4.52)       
No n=23 Not reached  1       1       
Leukocyte count n=61   
1.04 (1.01-
1.06) 0.007 
1.06 (1.02-
1.10) 0.005 
1.03 (1.01-
1.06) 0.011 
1.05 (1.01-
1.08) 0.005 
Absolute CD4 count 
n=59   1 0.146     1 0.265     
Sézary cell count n=47   1 0.123     1 0.204     
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Figure legend: 
 
 
Figure 1. Survival curves. Disease-specific survival (a) and overall survival curve (b) according 
the groups with and without upregulation of PLS3.  
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